AstraZeneca Korea announced on the 14th that it has signed a partnership contract with Ildong for gastroesophageal reflux disease treatment "Nexium (Esomeprazole)" and type 2 diabetes treatment "Qtern (Dapagliflozin/Saxagliptin Monohydrate)."

Through this, Ildong Pharmaceutical will jointly sell Nexium and Qtern with AstraZeneca Korea from January 1 next year. In 2014, the two companies promoted Onglyza and Komblyze XR (Metformin HCl/Saxaglipin Monohydrate).
Ildong Pharmaceutical has succeeded in marketing H2 receptor antagonists, PPI drugs, and functional dyspepsia treatments. Ildong Pharmaceutical plans to grow Nexium into an item with annual sales of more than 50 billion won in the future. Las